Scott N Gettinger

6PUBLICATIONS
109CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 10, 2024
Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.

Scott N Gettinger, Zihe Song, Karen L Reckamp

|Apr 02, 2024
Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.

Adam J Schoenfeld, Sylvia M Lee, Bernard Doger de Spéville

|Feb 15, 2024
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.

Bomiao Hu, Marc Wiesehöfer, Fernando J de Miguel

|Jan 26, 2024
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.

Edwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose

|Apr 21, 2023
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).

Shing M Lee, Weijia Fan, Aijin Wang

|Jan 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Hossein Borghaei, Scott Gettinger, Everett E Vokes

Pageof 1

Frequent Collaborators

2 joint publications

Lyudmila Bazhenova

2 joint publications

Roy S Herbst

2 joint publications

Mary W Redman

1 joint publications

Keith T Flaherty